Jupiter Neurosciences, Inc.
As of Oct 22, 2026, Jupiter Neurosciences is in Stage 4, the downtrend phase, now in week 40 (since Jan 12, 2026). It closed at $2.58, 98.0% below its 52-week high and below its 200-day average, which is falling.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is JUNS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
JUNS among Biotechnology539th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …539 | JUNS | Stage 4 · wk 40 | 4 | −13.1% |
Jupiter Neurosciences: quick answers
What stage is Jupiter Neurosciences in?
As of Oct 22, 2026, Jupiter Neurosciences (JUNS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jan 12, 2026 and is in week 40. What the four stages mean
Is Jupiter Neurosciences in an uptrend?
No. Jupiter Neurosciences is in a Stage 4 downtrend. It trades 88.6% below its 200-day average, which is falling.
How far is Jupiter Neurosciences from its 52-week high?
Jupiter Neurosciences closed at $2.58 on Oct 22, 2026, 98.0% below its 52-week high of $127.50. Its 52-week low is $2.42.
How has Jupiter Neurosciences performed over the past year?
As of Oct 22, 2026, Jupiter Neurosciences is down 97.9% over the past year and down 96.6% so far in 2026.
Which sector and industry is Jupiter Neurosciences in?
Jupiter Neurosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.